Results 21 to 30 of about 11,153 (206)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2010
Michael A Via1, Himani Chandra2, Takako Araki1, Matthew V Potenza3, Maria Skamagas41Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA; 2Division of Endocrinology, Diabetes and ...
Via MA
doaj   +2 more sources

<i>Artemisia argyi</i> Extracts Modulate Prolactin and Prostaglandin Pathways in Estrogen-Stimulated GH3 Cells and a Hyperprolactinemia Mouse Model. [PDF]

Food Sci Nutr
Artemisia argyi extracts suppress prolactin secretion, restore reproductive hormones, and modulate prostaglandin balance and inflammation in GH3 cells and a hyperprolactinemia mouse model. ABSTRACT Artemisia argyi (Pyeong‐an‐ae) has long been used in traditional medicine for gynecological conditions; however, its efficacy in treating premenstrual ...
Ma MJ, Lee J, Park J, Son D, Kim HJ, Jo YH, Lee SB, Kim GD, Choi EJ, Seo MS, Choi JH.   +10 more
europepmc   +2 more sources

Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma. [PDF]

Clin Transl Med
Retroperitoneal sarcoma cells can secrete prolactin into the bloodstream, inducing hyperprolactinaemia, which subsequently triggers metabolic reprogramming, such as glucose metabolism. SOX4 can function as a transcription factor that facilitates PRL transcription.
Xie F, Gu L, Yang K, Wang S, Xiao M, Yan G, Zhang Q, Liang R, Zhuang A, Xi Z, Niu Y, Chen Y, Xia X, Qu L, Zhao B, Li W, Wu T, Yu C, Luo C, Wang H, Lian L, Li W.   +21 more
europepmc   +2 more sources

Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine

iScience, 2022
Summary: Bromocriptine is approved as a diabetes therapy, yet its therapeutic mechanisms remain unclear. Though bromocriptine’s actions have been mainly attributed to the stimulation of brain dopamine D2 receptors (D2R), bromocriptine also targets the ...
Despoina Aslanoglou, Suzanne Bertera, Laura Friggeri, Marta Sánchez-Soto, Jeongkyung Lee, Xiangning Xue, Ryan W. Logan, J. Robert Lane, Vijay K. Yechoor, Peter J. McCormick, Jens Meiler, R. Benjamin Free, David R. Sibley, Rita Bottino, Zachary Freyberg   +14 more
doaj   +1 more source

Study on Synergistic Effect of Bromocriptine and Sitagliptin in Streptozotocin-induced Diabetic Rats [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Diabetes mellitus is a potentially morbid condition with high prevalence worldwide. Restoration of euglycemia in type 2 diabetes mellitus is difficult to achieve due to its multifactorial pathogenesis and frequently requires multiple ...
Govindaraj Nileshraj, Chandrasekaran Swithraa, Murugesan Sakthibalan, Maruti Shripati Sawadkar   +3 more
doaj   +1 more source

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas

BMC Endocrine Disorders, 2021
Background Prolactinoma is a functional pituitary adenoma that secretes excessive prolactin. Dopamine agonists (DAs) such as bromocriptine (BRC) are the first-line treatment for prolactinomas, but the resistance rate is increasing year by year, creating ...
Shuman Wang, Aihua Wang, Yu Zhang, Kejing Zhu, Xiong Wang, Yonggang Chen, Jinhu Wu   +6 more
doaj   +1 more source

Impact of Nano-Bromocriptine on Egg Production Performance and Prolactin Expression in Layers

Animals, 2021
The current study aimed to investigate the potential use of nano-bromocriptine in improving the laying performance of late laying hens by modulating the prolactin gene expression.
Ahmed Dawod, Noha Osman, Hanim S. Heikal, Korany A. Ali, Omaima M. Kandil, Awad A. Shehata, Hafez M. Hafez, Hamada Mahboub   +7 more
doaj   +1 more source

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis

Frontiers in Endocrinology, 2023
ObjectiveBromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical trial. The underlying mechanism contributing to the treatment effect is however unknown.
Yiqun Tang, Sakthivignesh Ponandai-srinivasan, Caroline Frisendahl, Johanna K. Andersson, Dora Pavone, Elizabeth A. Stewart, Parameswaran Grace Luther Lalitkumar, Eberhard Korsching, Nageswara Rao Bogavarappu, Kristina Gemzell-Danielsson   +9 more
doaj   +1 more source

Bromocriptine in Parkinsonism [PDF]

BMJ, 1974
Bromocriptine, a drug acting directly upon dopaminergic receptors, has been found to have a significant therapeutic action in a double-blind study of 20 patients with idiopathic Parkinsonism who were already receiving conventional therapy, including levodopa.
D B, Calne, P F, Teychenne, L E, Claveria, R, Eastman, J K, Greenacre, A, Petrie   +5 more
openaire   +2 more sources

Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study

BMC Endocrine Disorders, 2020
Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr, Thida C. Tan, Joan C. Lo, Jonathan G. Zaroff, Grace H. Tabada, Jingrong Yang, Alan S. Go   +6 more
doaj   +1 more source